Grant: Fellowship - Priority Announcement: Evidence Informed Healthcare Renewal
Direct Payment
$100,000.00
Cost-Effectiveness of Using BRCA1/2 Genetic Testing to Guide Breast Cancer Treatment: An Observational Study of Women in the United Sates.
EF 2011-12
Résumé
Genetic testing can be used to detect patients with higher risk of recurrence or spread of breast cancer. Current clinical guidelines suggest that patients with higher risk of breast cancer recurrence or metastasis should be referred for genetic testing to determine whether they may need more aggressive treatment in order to reduce risk of recurrence. Considering the hereditary nature of some subtypes of breast cancer, a positive test result may also be used to recommend monitoring of at-risk relatives of affected patients. This study aims to use large, nation-wide observational databases to: 1) assess clinical benefits and economic costs of using genetic testing to guide treatment of breast cancer among women, and 2) investigate health disparities in access to genetic tests and appropriate follow-up care among minorities and lower income patients across the US. This study will investigate both clinical benefits and costs that are associated with genetic testing and therefore will inform policy makers and practitioners about the overall cost benefit trade-off of using genetic testing to guide treatment of breast cancer. Furthermore, this study will investigate the existing gaps in terms of equal access to health care resources (using the example of genetic tests for breast cancer) among minorities and low income patients. This is the first study about the clinical and economic value of genetic testing for breast cancer based on a large observational data. My research will generate useful empirical and methodological results for health policy makers and may potentially be used to improve clinical guidelines for using genetic testing for breast cancer.
Programme
Fellowship - Priority Announcement: Evidence Informed Healthcare Renewal
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
243108
Name
Najafzadeh Mehdi
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Health systems / services
Prcname2
Health Research Training A - Post-PhD (HTA)
Projecttitle
Cost-Effectiveness of Using BRCA1/2 Genetic Testing to Guide Breast Cancer Treatment: An Observational Study of Women in the United Sates.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Evidence Informed Healthcare Renewal
Keyworddelim
Breast Cancer; Cost- Effectiveness; Genetic Testing; Health Disparities
Abstract
Genetic testing can be used to detect patients with higher risk of recurrence or spread of breast cancer. Current clinical guidelines suggest that patients with higher risk of breast cancer recurrence or metastasis should be referred for genetic testing to determine whether they may need more aggressive treatment in order to reduce risk of recurrence. Considering the hereditary nature of some subtypes of breast cancer, a positive test result may also be used to recommend monitoring of at-risk relatives of affected patients. This study aims to use large, nation-wide observational databases to: 1) assess clinical benefits and economic costs of using genetic testing to guide treatment of breast cancer among women, and 2) investigate health disparities in access to genetic tests and appropriate follow-up care among minorities and lower income patients across the US. This study will investigate both clinical benefits and costs that are associated with genetic testing and therefore will inform policy makers and practitioners about the overall cost benefit trade-off of using genetic testing to guide treatment of breast cancer. Furthermore, this study will investigate the existing gaps in terms of equal access to health care resources (using the example of genetic tests for breast cancer) among minorities and low income patients. This is the first study about the clinical and economic value of genetic testing for breast cancer based on a large observational data. My research will generate useful empirical and methodological results for health policy makers and may potentially be used to improve clinical guidelines for using genetic testing for breast cancer.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Najafzadeh, Mehdi
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~